MedPath

The effect of topical application of human milk ,chlorhexidinon on umbilical cord of newbor

Not Applicable
Conditions
Certain conditions originating in the perinatal period.
Omphalitis of newborn with or without mild haemorrhage
Registration Number
IRCT201010285038N1
Lead Sponsor
Kashan University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
261
Inclusion Criteria

Criteria for Inclusion:
Newborns with gestational age 42-37 weeks; Apgar score higher than 7 at minute 1; rupture of membranes for no longer than 12 hours; The cord cut in sterile condition in the delivery room and don't use antiseptic agent on the stump.

criteria for excluded:
Infants with perinatal asphyxia, respiratory distress, metabolic disease, and any other problems that requiring immediate refer to neonatal Intensive Care Unit ; Infants with immediate need of evaluation and treatment; Newborns with any congenital disorder or disease; Infants of mothers with postpartum fever, mastitis, Urogenital infection; If the mother does not live in the city of Kashan(live in Rural); If the mother is the Afghani.

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
mbilical cord separation time. Timepoint: from birth to Cord separation time. Method of measurement: Researcher observed.;Infection Umbilical cord. Timepoint: the first three hours after birth , days 3 and 7 after intervention ,2 days after umbilical cord separation. Method of measurement: Culture of samples.
Secondary Outcome Measures
NameTimeMethod
Complications and problems such as leakage of blood, discharge and granuloma tissue. Timepoint: the first three hours after birth , days 3 and 7 after intervention ,2 days after umbilical cord separation. Method of measurement: Observed by the researcher and visited by neonatologist if there is any cord related adverse events.
© Copyright 2025. All Rights Reserved by MedPath